Concord Biotech has successfully commissioned and commenced production at its newly established injectable manufacturing facility, Unit-4, located in Valthera. This advanced unit is a key milestone in the company’s strategic growth, reinforcing its commitment to innovation and excellence in pharmaceutical manufacturing.
Designed to meet stringent international standards, the Valthera facility is equipped with cutting-edge technology to ensure the consistent production of high-quality injectable formulations. With a focus on precision, safety, and efficiency, the new unit enhances Concord Biotech’s capabilities in addressing global healthcare needs.
In the exchange filing, Concord Biotech shared, “The company has successfully commissioned and commenced production of injectable at our new manufacturing facility situated at Valthera, This advanced facility has been meticulously designed and constructed to adhere to stringent international standards, equipped with cutting-edge technology to ensure the consistent delivery of high-quality products.”
The operationalization of Unit-4 aligns with the company’s long-term vision of expanding its manufacturing footprint and strengthening its position in the pharmaceutical industry. By integrating advanced automation and compliance-driven processes, Concord Biotech aims to cater to both domestic and international markets with superior-quality injectable products.
